is teaming with to develop a potential cancer treatment drug.

Huya is based in China and has an operation in San Diego, Calif.

Quintiles, the world’s largest life sciences services firm, is expanding its efforts at new drug development in partnership with pharma and biotech firms such as Huya.

Financial terms of the Huya agreement were not disclosed.

Huya works with research institutions and other drug firms in China to find potential drugs. Huya licensed the compound for co-development with Quintiles from Chipscreen Bioscience in China.

Quintiles will work with Huya on a Phase I clinical trial in the U.S. A first-stage trial has already been completed in China.

“This agreement will help accelerate the development of medicines from China,” said Tom Perkins, a senior vice president at Quintiles. “It illustrates Quintiles’ ability to draw upon its breadth of services to build alliances that help biopharmaceutical companies navigate the New Health [Quintiles’ recently launched development and marketing program], and further illustrates our strategy to maximize the potential of global biopharmaceutical development and innovation for the benefit of patients.”

Get the latest news alerts: at Twitter.